The JAK-STAT pathway: A therapeutic target in hematological malignancies

Current Cancer Drug Targets

Volumn 6, Issue 8, 2006, Pages 671-679

  Ferrajoli, A ^a   Faderl, S ^a   Ravandi, F ^a   Estrov, Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hematological malignancies; JAK STAT pathway; Targeted therapy

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALEMTUZUMAB; ANTISENSE OLIGONUCLEOTIDE; BUTYRIC ACID; CURCUMIN; DASATINIB; DOXORUBICIN; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; JANUS KINASE; JANUS KINASE 2; LONAFARNIB; MONOCLONAL ANTIBODY; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OLIGONUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; ROSIGLITAZONE; SMALL INTERFERING RNA; STAT PROTEIN; SULINDAC; TIPIFARNIB; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; WHI P 154;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL TRANSFORMATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DIMERIZATION; DNA BINDING; ENZYME INHIBITION; GENE DELETION; GENE MUTATION; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LARGE CELL LYMPHOMA; LARGE GRANULAR LYMPHOCYTE; LYMPHATIC LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOPHYSIOLOGY; POLYCYTHEMIA VERA; PROMYELOCYTIC LEUKEMIA; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SEZARY SYNDROME; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; ANTIBODIES, MONOCLONAL; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASES; HUMANS; JANUS KINASES; PPAR GAMMA; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 33845348577     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906779010227     Document Type: Review

References (88)

1. Rane, S. G.; Reddy, E. P. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002, 21, 3334-3358.
2. Sadowski, H. B.; Shuai, K.; Darnell, J. E., Jr.; Gilman, M. Z. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993, 261, 1739-1744.
3. Darnell, J. E., Jr.; Kerr, I. M.; Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415-1421.
4. Kisseleva, T.; Bhattacharya, S.; Braunstein, J.; Schindler, C. W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002, 285, 1-24.
5. Saharinen, P.; Silvennoinen, O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 2002, 277, 47954-47963.
6. Gu, J.; Wang, Y.; Gu, X. Evolutionary analysis for functional divergence of Jak protein kinase domains and tissue-specific genes. J. Mol. Evol. 2002, 54, 725-733.
7. Yeh, T. C.; Pellegrini, S. The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell. Mol. Life Sci. 1999, 55, 1523-1534.
8. Ward, A. C.; Touw, I.; Yoshimura, A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000, 95, 19-29.
9. Rodig, S. J.; Meraz, M. A.; White, J. M.; Lampe, P. A.; Riley, J. K; Arthur, C. D.; King, K. L.; Sheehan, K. C.; Yin, L.; Pennica, D.; Johnson, E. M., Jr.; Schreiber, R. D. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93, 373-383.
10. Neubauer, H.; Cumano, A.; Muller, M.; Wu, H.; Huffstadt, U.; Pfeffer, K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93, 397-409.
11. Notarangelo, L. D.; Giliani, S.; Mazza, C.; Mella, P.; Savoldi, G.; Rodriguez-Perez, C.; Mazzolari, E.; Fiorini, M.; Duse, M.; Plebani, A.; Ugazio, A. G.; Vihinen, M.; Candotti, F.; Schumacher, R. F. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(C)-JAK3 signaling pathway as a model. Immunol. Rev. 2000, 178, 39-48
12. Nosaka, T.; van Deursen, J. M.; Tripp, R. A.; Thierfelder, W. E.; Witthuhn, B. A.; McMickle, A. P.; Doherty, P. C.; Grosveld, G. C.; Ihle, J. N. Defective lymphoid development in mice lacking Jak3. Science 1995, 270, 800-802.
13. Park, S. Y.; Saijo, K.; Takahashi, T.; Osawa, M.; Arase, H.; Hirayama, N.; Miyake, K.; Nakauchi, H.; Shirasawa, T.; Saito, T. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995, 3, 771-782.
14. Seto, Y.; Nakajima, H.; Suto, A.; Shimoda, K.; Saito, Y.; Nakayama, K. I.; Iwamoto, I. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J. Immunol. 2003, 170, 1077-1083.
15. Durbin, J. E.; Hackenmiller, R.; Simon, M. D.; Levy, D. E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996, 84, 443-450.
16. Meraz, M. A.; White, J. M.; Sheehan, K. C.; Bach, E. A.; Rodig, S. J.; Dighe, A. S.; Kaplan, D. H.; Riley, J. K.; Greenlund, A. C.; Campbell, D.; Carver-Moore, K.; DuBois, R. N.; Clark, R.; Aguet, M.; Schreiber, R. D. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84, 431-442.
17. Levy, D. E. Physiological significance of STAT proteins: investigations through gene disruption in vivo. Cell. Mol. Life Sci. 1999, 55, 1559-1557.
18. Park, C.; Li, S.; Cha, E.; Schindler, C. Immune response in Stat2 knockout mice. Immunity 2000, 13, 795-804.
19. Takeda, K.; Noguchi, K.; Shi, W.; Tanaka, T.; Matsumoto, M.; Yoshida, N.; Kishimoto, T.; Akira, S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 1997, 94, 3801-3804.
20. Sano, S.; Itami, S.; Takeda, K.; Tarutani, M.; Yamaguchi, Y.; Miura, H.; Yoshikawa, K.; Akira, S.; Takeda, J. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999, 18, 4657-4668.
21. Takeda, K.; Kaisho, T.; Yoshida, N.; Takeda, J.; Kishimoto, T.; Akira, S. Stat3 activation is responsible for IL-6-dependent T-cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J . Immunol. 1998, 161, 4652-4660.
22. Takeda, K.; Clausen, B. E.; Kaisho, T.; Tsujimura, T.; Terada, N.; Forster, I.; Akira, S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10, 39-49.
23. Kaplan, M. H.; Sun, Y. L.; Hoey, T.; Grusby, M. J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996, 382, 174-177.
24. Thierfelder, W. E.; van Deursen, J. M.; Yamamoto, K.; Tripp, R. A.; Sarawar, S. R.; Carson, R. T.; Sangster, M. Y.; Vignali, D. A.; Doherty, P. C.; Grosveld, G. C.; Ihle, J. N. Requirement for Stat4 interleukin-12-mediated responses of natural killer and T cells. Nature 1996, 382, 171-174.
25. Teglund, S.; McKay, C.; Schuetz, E.; van Deursen, J. M.; Stravopodis, D.; Wang, D.; Brown, M.; Bodner, S.; Grosveld, G.; Ihle, J. N. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998, 93, 841-850.
26. Socolovsky, M.; Fallon, A. E.; Wang, S.; Brugnara, C.; Lodish, H. F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/5b-/-mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999, 98, 181-191.
27. Feldman, G. M.; Rosenthal, L. A.; Liu, X.; Hayes, M. P.; Wynshaw-Boris, A.; Leonard, W. J.; Hennighausen, L.; Finbloom, D. S. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 1997, 90, 1768-1776.
28. Shimoda, K.; van Deursen, J.; Sangster, M. Y.; Sarawar, S. R.; Carson, R. T.; Tripp, R. A.; Chu, C.; Quelle, F. W.; Nosaka, T.; Vignali, D. A.; Doherty, P. C.; Grosveld, G.; Paul, W. E.; Ihle, J. N. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996, 380, 630-633.
29. Takeda, K.; Kamanaka, M.; Tanaka, T.; Kishimoto, T.; Akira, S. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J. Immunol. 1996, 157, 3220-3222.
30. Kieslinger, M.; Woldman, I.; Moriggl, R.; Hofmann, J.; Marine, J. C.; Ihle, J. N.; Beug, H.; Decker, T. Genes Dev. 2000, 14, 232-244.
31. Socolovsky, M.; Nam, H.; Fleming, M. D.; Haase, V. H.; Brugnara, C.; Lodish, H. F. Ineffective erythropoiesis in Stat5a (-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001, 98, 3261-3273.
32. Hirokawa, S.; Sato, H.; Kato, I.; Kudo, A. EBF-regulating Pax5 transcription id enhanced by STAT5 in the early stage of B cells. Eur. J. Immunol. 2003, 33, 1824-1829.
33. Soldevilla, G.; Licona, I.; Salgado, A.; Ramirez, M.; Chavez, R.; Garcia-Zepeda, E. Impaired chemokine-induced migration during T-cell development in the absence of Jak 3. Immunology 2004, 112, 191-200.
34. Niwa, H.; Burdon, T.; Chambers, I.; Smith, A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998, 12, 2048-2060.
35. James, C.; Ugo, V.; Le Couedic, J. P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garcon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; Villeval, J. L.; Constantinescu, S. N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434, 1144-1148.
36. Baxter, E. J.; Scott, L. M.; Campbell, P. J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G. S.; Bench, A. J..; Boyd, E. M.; Curtin, N.; Scott, M. A.; Erber, W. N.; Green, A. R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365, 1054-1061.
37. Levine, R. L.; Wadleigh, M.; Cools, J.; Ebert, B. L.; Wernig, G.; Huntly, B. J.; Boggon, T. J.; Wlodarska, I.; Clark, J. J.; Moore, S.; Adelsperger, J.; Koo, S.; Lee, J. C.; Gabriel, S.; Mercher, T.; D'Andrea, A.; Frohling, S.; Dohner, K.; Marynen, P.; Vandenberghe, P.; Mesa, R. A.; Tefferi, A.; Griffin, J. D.; Eck, M.J.; Sellers, W. R.; Meyerson, M.; Golub, T. R.; Lee, S. J.; Gilliland, D. G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7, 387-397.
38. Kralovics, R.; Passamonti, F.; Buser, A. S.; Teo, S. S.; Tiedt, R.; Passweg, J. R.; Tichelli, A.; Cazzola, M.; Skoda, R. C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352, 1779-1790.
39. Jones, A. V.; Kreil, S.; Zoi, K.; Waghorn, K.; Curtis, C.; Zhang, L.; Score, J.; Seear, R.; Chase, A. J.; Grand, F. H.; White, H.; Zoi, C.; Loukopoulos, D.; Terpos, E.; Vervessou, E. C.; Schultheis, B.; Emig, M.; Ernst, T.; Lengfelder, E.; Hehlmann, R.; Hochhaus, A.; Oscier, D.; Silver, R. T.; Reiter, A.; Cross, N. C. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106, 2162-2168.
40. Jelinek, J.; Oki, Y.; Gharibyan, V.; Bueso-Ramos, C.; Prchal, J. T.; Verstovsek, S.; Beran, M.; Estey, E.; Kantarjian, H. M.; Issa, J. P. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 2005, 106, 3370-3373.
41. Tono, C.; Xu, G.; Toki, T.; Takahashi, Y.; Sasaki, S.; Terui, K.; Ito, E. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. Leukemia 2005, 19, 1843-1844.
42. Lacronique, V.; Boureaux, A.; Valle, V. D.; Poirel, H.; Quang, C. T.; Mauchauffe, M.; Berthou, C.; Lessard, M.; Berger, R.; Ghysdael, J.; Bernard, O. A. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278, 1309-1312.
43. Takemoto, S.; Mulloy, J. C.; Cereseto, A.; Migone, T. S.; Patel, B. K.; Matsuoka, M.; Yamaguchi, K.; Takatsuki, K.; Kamihira, S.; White, J. D.; Leonard, W. J.; Waldmann, T.; Franchini, G. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl. Acad. Sci. USA 1997, 94, 13897-13902.
44. Peeters, P.; Raynaud, S. D.; Cools, J.; Wlodarska, I.; Grosgeorge, J.; Philip, P.; Monpoux, F.; Van Rompaey, L.; Baens, M.; Van den Berghe, H.; Marynen, P. Fusion of TEL, The ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90, 2535-2540.
45. Schwaller, J.; Fantsve, J.; Aster, J.; Williams, I. R.; Tomasson, M. H.; Ross, T. S.; Peeters, P.; Van Rompaey, L.; Van Etten, R. A.; Ilaria, R., Jr.; Marynen, P.; Gilliland, D. G. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998, 17, 5321-5333.
46. Zhang, Q.; Lee, B.; Korecka, M.; Li, G.; Weyland, C.; Eck, S.; Gessain, A.; Arima, N.; Lessin, S. R.; Shaw, L. M.; Luger, S.; Kamoun, M.; Wasik, M. A. Differences in posphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2 independent and IL-2 dependent cell lines and uncultured leukemia cells from patients with adult T-cell lymphoma/leukemia. Leuk. Res. 1999, 23, 373-384.
47. Showe, L. C.; Fox, F. E.; Williams, D.; Au, K.; Niu, Z.; Rook, A. H. Depressed IL-12-mediated signal transduction in T cells from patients withSezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. J. Immunol. 1999, 163, 4073-4079.
48. Nielson, M.; Kaltoft, K.; Nordhahl, M.; Ropke, C.; Geisler, C.; Mustelin, T.; Dobson, P.; Svejgaard, A.; Odum, N. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tryphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. USA 1997, 94, 6764-6769.
49. Zhang, Q.; Nowak, I.; Vonderheid, E. C.; Rook, A. H.; Kadin, M. E.; Nowell, P. C.; Shaw, L. M.; Wasik, M. A. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA 1996, 93, 9148-9153.
50. Biethahn, S.; Alves, F.; Wilde, S.; Hiddemann, W.; Spiekermann, K. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp. Hematol. 1999, 27, 885-894.
51. Gouilleux-Gruart, V.; Gouilleux, F.; Desaint, C.; Claisse, J. F.; Capiod, J. C.; Delobel, J.; Weber-Nordt, R.; Dusanter-Fourt, I.; Dreyfus, F.; Groner, B.; Prin, L. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996, 87, 1692-1697.
52. Aronica, M. G.; Brizzi, M. F.; Dentelli, P.; Rosso, A.; Yarden, Y.; Pegoraro, L. p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells. Oncogene 1996, 13, 1017-1026.
53. Birkenkamp, K. U.; Geugien, M.; Lemmink, H. H.; Kruijer, W.; Vellenga, E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001, 15, 1923-1931.
54. Benekli, M.; Xia, Z.; Donohue, K. A.; Ford, L. A.; Pixley, L. A.; Baer, M. R.; Baumann, H.; Wetzler, M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002, 99, 252-257.
55. Arnould, C.; Philippe, C.; Bourdon, V.; Grgoire, M. J.; Berger, R.; Jonveaux, P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum. Mol. Genet. 1999, 8, 1741-1749.
56. Maurer, A. B.; Wichmann, C.; Gross, A.; Kunkel, H.; Heinzel, T.; Ruthardt, M.; Groner, B.; Grez, M. The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood 2002, 99, 2647-2652.
57. Dong, S.; Tweardy, D. J. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 2002, 99, 2637-2646.
58. Carlesso, N.; Frank, D. A.; Griffin, J. D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 1996, 183, 811-820.
59. Ilaria, R. L., Jr.; Van Etten, R. A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 1996, 271, 31704-31710.
60. Frank, D. A.; Varticovski, L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996, 10, 1724-1730.
61. Nieborowska-Skorska, M.; Wasik, M. A.; Slupianek, A.; Salomoni, P.; Kitamura, T.; Calabretta, B.; Skorski, T. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 1999, 189, 1229-1242.
62. Nieborowska-Skorska, M.; Slupianek, A.; Skorski, T. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells. Oncogene 2000, 19, 4117-4124.
63. Donato, N. J.; Wu, J. Y.; Zhang, L.; Kantarjian, H.; Talpaz, M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 2001, 97, 2846-2853.
64. Sexl, V.; Piekorz, R.; Moriggl, R.; Rohrer, J.; Brown, M. P.; Bunting, K. D.; Rothammer, K.; Roussel, M. F.; Ihle, J. N. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 2000, 96, 2277-2283.
65. Lemmink, H. H.; Tuyt, L.; Knol, G.; Krikke, E.; Vellenga, E. Identification of LIL-STAT in monocytic leukemia cells and monocytes after stimulation with interleukin-6 or interferon gamma. Blood 2001, 98, 3849-3852.
66. Frank, D. A.; Mahajan, S.; Ritz, J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest. 1997, 100, 3140-3148.
67. Catlett-Falcone, R.; Landowski, T. H.; Oshiro, M. M.; Turkson, J.; Levitzki, A.; Savino, R.; Ciliberto, G.; Moscinski, L.; Fernandez-Luna, J. L.; Nunez, G.; Dalton, W. S.; Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10, 105-115.
68. Quintanilla-Martinez, L.; Kremer, M.; Specht, K.; Calzada-Wack, J.; Nathrath, M.; Schaich, R.; Hofler, H.; Fend, F. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am. J. Pathol. 2003, 162, 1449-1461.
69. Zamo, A.; Chiarle, R.; Piva, R.; Howes, J.; Fan, Y.; Chilosi, M.; Levy, D. E.; Inghirami, G. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002, 21, 1038-1047.
70. Nieborowska-Skorska, M.; Slupianek, A.; Xue, L.; Zhang, Q.; Raghunath, P. N.; Hoser, G.; Wasik, M. A.; Morris, S. W.; Skorski, T. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 2001, 61, 6517-6523.
71. Zhang, Q.; Raghunath, P. N.; Xue, L.; Majewski, M.; Carpentieri, D. F.; Odum, N.; Morris, S. W.; Skorski, T.; Wasik, M. A. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 2002, 168, 466-474.
72. Amin, H. M.; Medeiros, L. J.; Ma, Y.; Feretzaki, M.; Das, P.; Leventaki, V.; Rassidakis, G. Z.; O'Connor, S. L.; McDonnell, T. J.; Lai, R. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003, 22, 5399-5407.
73. Thomas, M.; Finnegan, C. E.; Rogers, K. M.; Purcell, J. W.; Trimble, A.; Johnston, P. G.; Boland, M. P. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res. 2004, 64, 8357-8354.
74. Klampfer, L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets 2006, 6, 107-121.
75. Jazirehi, A. R.; Bonavida, B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005, 24, 2121-2143.
76. Byrd, J. C.; Kitada, S.; Flinn, I. W.; Aron, J. L.; Pearson, M.; Lucas, D.; Reed, J. C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chonic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99, 1038-1043.
77. Klampfer, L.; Huang, J.; Sasazuki, T.; Shirasawa, S.; Augenlicht, L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol. Cancer Res. 2003, 1, 855-862.
78. Sanchez-Gonzalez, B.; Yang, H.; Bueso-Ramos, C.; Hoshino, K.; Quintas-Cardama, A.; Richon, V. M.; Garcia-Manero, G. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006, 108, 1174-1182.
79. Park, E. J.; Park, S. Y.; Joe, E. H.; Jou, I. 15dPGJ12 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J. Biol. Chem. 2003, 278, 14747-14752.
80. Tontonoz, P.; Nagy, L.: Alvarez, J. G.; Thomazy, V. A.; Evans, R. M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93, 241-252.
81. Nikitakis, N. G.; Hamburger, A. W.; Sauk, J. J. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cel carcinoma cells. Cancer Res. 2002, 62, 1004-1007.
82. Kim, H. Y.; Park, E. J.; Joe, E. H.; Jou, I. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J. Immunol. 2003, 171, 6072-6079.
83. Ciardiello, F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol. 2005 1, 221-234
84. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163-1167.
85. Meydan, N.; Grunberger, T.; Dadi, H.; Shahar, M.; Arpaia, E.; Lapidot, Z.; Leeder, J. S.; Freedman, M.; Cohen, A.; Gazit, A.; Levitzki, A.; Roifman, C. M. Inhibition of acute lymphoblastic leukaemia by a JAK-2 inhibitor. Nature 1996, 379, 645-648.
86. Luo, C.; Laaja, P. Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov. Today 2004, 9, 268-275.
87. Faderl, S.; Ferrajoli, A.; Harris, D.; Van, Q.; Priebe, W.; Estrov, Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Blood 2005, 25, 1841-1850.
88. Leong, P. L.; Andrews, G. A.; Johnson, D. E.; Dyer, K. F.; Xi, S.; Mai, J. C.; Robbins, P. D.; Gadiparthi, S.; Burke, N. A.; Watkins, S. F.; Grandis, J. R. Targeted inhibition of Stat 3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA 2003, 100(7), 4138-4143.